|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0006142,
umls-concept:C0085862,
umls-concept:C0279752,
umls-concept:C0597345,
umls-concept:C0746319,
umls-concept:C1299583,
umls-concept:C1413052,
umls-concept:C1514475,
umls-concept:C1516213,
umls-concept:C1549571,
umls-concept:C1608386
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2006-11-6
|
|
pubmed:abstractText |
Hypoxia in breast cancer is associated with poor prognosis and down-regulation of the estrogen receptor. Carbonic anhydrase IX (CA IX) is a hypoxia-inducible gene that has been associated with poor outcome in many epithelial cancers. Previous studies of CA IX in breast cancer have been carried out on mixed cohorts of premenopausal and postmenopausal patients with locally advanced disease and varying treatment regimens. We examined the potential prognostic and predictive role of CA IX in premenopausal breast cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/CA9 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CCNA2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Carbonic Anhydrases,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin A,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin A2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoxia-Inducible Factor 1, alpha...,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6421-31
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17085655-Adult,
pubmed-meshheading:17085655-Antigens, Neoplasm,
pubmed-meshheading:17085655-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17085655-Blotting, Western,
pubmed-meshheading:17085655-Breast Neoplasms,
pubmed-meshheading:17085655-Carbonic Anhydrases,
pubmed-meshheading:17085655-Chemotherapy, Adjuvant,
pubmed-meshheading:17085655-Cyclin A,
pubmed-meshheading:17085655-Cyclin A2,
pubmed-meshheading:17085655-Cyclin D1,
pubmed-meshheading:17085655-Cyclin E,
pubmed-meshheading:17085655-Female,
pubmed-meshheading:17085655-Humans,
pubmed-meshheading:17085655-Hypoxia-Inducible Factor 1, alpha Subunit,
pubmed-meshheading:17085655-Immunohistochemistry,
pubmed-meshheading:17085655-Ki-67 Antigen,
pubmed-meshheading:17085655-Lymphatic Metastasis,
pubmed-meshheading:17085655-Mastectomy, Segmental,
pubmed-meshheading:17085655-Middle Aged,
pubmed-meshheading:17085655-Premenopause,
pubmed-meshheading:17085655-Prognosis,
pubmed-meshheading:17085655-Radiation Tolerance,
pubmed-meshheading:17085655-Radiotherapy,
pubmed-meshheading:17085655-Receptors, Estrogen,
pubmed-meshheading:17085655-Receptors, Progesterone,
pubmed-meshheading:17085655-Survival Analysis,
pubmed-meshheading:17085655-Tamoxifen,
pubmed-meshheading:17085655-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
|
|
pubmed:affiliation |
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College, Dublin, and Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital, Ireland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
